Skip to main content

Table 2 Risk of bias for included studies

From: The impact of Pegylated liposomal doxorubicin in recurrent ovarian cancer: an updated meta-analysis of randomized clinical trials

Study Random sequence generation Allocation concealment Blinding of participants and personnel Blinding of outcome assessment Incomplete outcome data Selective reporting other bias
Pujade-Lauraine2010 [13] Low risk Low risk High risk Low risk Low risk Low risk Low risk
Gladieff2012 [14] Low risk Unclear risk High risk Low risk Low risk Low risk Low risk
Mahner2014 [15] Low risk Low risk High risk Low risk Low risk Low risk Low risk
Bafaloukos2010 [16] Low risk Low risk Unclear risk Low risk Low risk Low risk Low risk
Mutch2007 [17] Low risk Low risk High risk Unclear risk Unclear risk High risk Low risk
Ferrandina2008 [18] Low risk Low risk High risk Low risk Low risk Low risk Low risk
Vergote2009 [19] Low risk Low risk High risk Low risk Low risk Low risk Low risk
Colombo2012 [20] Low risk Low risk High risk Low risk Low risk Low risk Low risk
Banerjee2018 [21] Low risk Low risk High risk Low risk Low risk Low risk Low risk
Kaye2012 [22] Low risk Low risk High risk Low risk Low risk Low risk Low risk